<DOC>
	<DOCNO>NCT01196988</DOCNO>
	<brief_summary>This study design assess safety immunogenicity GlaxoSmithKline ( GSK ) Biologicals ' investigational vaccine GSK2321138A child age 3 17 year , describe safety immunogenicity GSK Biologicals ' investigational vaccine GSK2321138A child age 6 35 month .</brief_summary>
	<brief_title>Immunogenicity Safety Study GSK Biologicals ' Influenza Vaccine When Administered Children</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /Legally Acceptable Representative ( ) ( LAR ) comply requirement protocol . For non US country : Children , male female , age 6 month 17 year time first study vaccination . For US : Children , male female , age 3 17 year time first study vaccination Written inform consent obtain subject parent ( ) LAR ( ) subject . Assent obtain subject applicable . Subjects stable health determine investigator 's clinical examination assessment subject ' medical history . Written inform assent obtain subject if/as require local regulation . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative urine pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine plan use study period . Routine register childhood vaccination permit . Planned administration vaccine 30 day prior 30 day study vaccine administration . Acute chronic , clinicallysignificant pulmonary , cardiovascular , hepatic renal functional abnormality , determine medical history physical examination . Prior receipt seasonal pandemic influenza vaccine ( registered investigational ) within 6 month precede first dose study vaccine , plan use study period . Chronic administration immunosuppressant immunemodifying drug within three month prior enrolment study plan administration study period . Administration immunoglobulins and/or blood product within three month prior enrolment study , plan study . Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination . History seizure progressive neurological disease . History GuillainBarr√© syndrome within 6 week receipt prior inactivate influenza virus vaccine . Concurrently participate another clinical study , time study period subject expose investigational noninvestigational product . History hypersensitivity previous dose influenza vaccine , history reaction hypersensitivity likely exacerbate component vaccine Acute disease and/or fever time enrolment Ongoing aspirin therapy Pregnant lactate female Female planning become pregnant planning discontinue contraceptive precaution . Any condition , opinion investigator , prevents subject participate study Child Care .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GSK Biologicals influenza vaccine GSK2321138A</keyword>
	<keyword>influenza infection</keyword>
</DOC>